Sunshine Biopharma’s lead anti-tumor compound, Adva-27a, is cleared via a Cytochrome P450-independent mechanism
MONTREAL, July 25, 2011 /PRNewswire/ – Sunshine Biopharma Inc. (OTCBB:
SBFM) a development stage pharmaceutical company focused on the
research, development and commercialization of drugs for the treatment
of various forms of cancer, today announced that it has completed a
study in which the mechanism of clearance of the Company’s new drug,
Adva-27a, was analyzed using human liver microsomes in vitro.
Clearance refers to the mechanism by which a drug is metabolized and
eliminated by the body. One of the pathways for eliminating drugs by
the body involves the Cytochrome P450 catalytic cycle. In drug
development it is important to determine whether or not a given
compound of interest undergoes elimination through the Cytochrome P450
catalytic cycle as this natural process can produce toxic (poisonous)
intermediates which would render the compound unusable as a drug.
Studies of this nature are initially performed in vitro using human
liver microsomes containing or lacking Cytochrome P450 activity. The
results of such studies for the Company’s Adva-27a, revealed that this
compound is cleared by pathways which are independent of Cytochrome
P450. The observed intrinsic clearance rates (microliter per minute
per milligram protein) for Adva-27a were 60 and 43 in the presence and
absence of Cytochrome P450 activity, respectively.
“As a result of this study, Adva-27a meets yet another of the criteria
of a good pharmaceutical drug”, said Dr. Steve N. Slilaty, Sunshine’s
President and CEO. “In this type of study, the difference between 60
and 43 in terms of observed intrinsic clearance rate is not considered
significant. Scientifically, these data are interpreted as Adva-27a
undergoes Non-Cytochrome P450 mediated degradation”, he added.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements,
the success of the Company’s development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
SOURCE Sunshine Biopharma Inc.